Recombinant fusion proteins targeting CD47 and CD24, preparation and use thereof
AssigneeImmuneonco Biopharmaceuticals (Shanghai) Inc.
InventorsWenzhi Tian, Song Li, Dianze Chen
Life of this patent
Estimating the term…
Loading patent…
AssigneeImmuneonco Biopharmaceuticals (Shanghai) Inc.
InventorsWenzhi Tian, Song Li, Dianze Chen
Estimating the term…
The present application provides a recombinant fusion protein containing an anti-CD24 antibody or an antibody fragment thereof, with at least one paratope of the anti-CD24 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain or a light chain constituting that paratope, wherein the recombinant fusion protein can bind to CD47, CD24 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over expression of CD47 and/or CD24 using the recombinant fusion protein.
A recombinant fusion protein, comprising an anti-CD24 antibody or an antibody fragment thereof, and a CD47 binding peptide,
Dependencies are inferred from the claim text.